AI
CYTK icon

Atria Investments’s Cytokinetics CYTK Stock Holding History

Atria Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$856K Sell
12,980
-1,390
-10% -$88.3K 0.01% 1145
2025
Q4 		$913K Buy
14,370
+2,223
+18% +$138K 0.01% 1118
2025
Q3 		$668K Buy
+12,147
New +$500K 0.01% 1258

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Atria Investments's CYTK Position: Q1 2026 in Review

Atria Investments reduced its Cytokinetics (CYTK) stake by 9.7% in Q1 2026, selling an estimated $88.3K and leaving 12,980 shares worth $856K. The position accounts for 0.01% of the portfolio, ranked #1145.

Atria Investments first reported a position in CYTK in Q3 2025 and has held it in 3 quarters since. The position peaked at $913K in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Atria Investments held 12,980 shares of Cytokinetics worth $856K as of Q1 2026.
  • Atria Investments sold 1,390 Cytokinetics shares in Q1 2026, an estimated $88.3K.
  • Cytokinetics made up 0.01% of Atria Investments's portfolio in Q1 2026, its #1145 holding.
  • Atria Investments first reported a position in Cytokinetics in Q3 2025 and has held it in 3 quarters since.
  • Atria Investments's Cytokinetics position peaked at $913K in Q4 2025.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Atria Investments's 13F filing for Q1 2026, filed 5 May 2026.